Eastgate Biotech Stock

Eastgate Biotech Corp. engages in the development of formulations of natural compounds and pharmaceutical products.

The company has started marketing and distribution and has limited sales for some of its nutraceuticals products. Its self-emulsifying drug delivery technology includes two approaches that could ultimately improve solubility of poorly soluble compounds and provide new methods of delivery. These perceived approaches consist of a self-nanoemulsifying vehicle for oral or topical use, and a technological approach intended to improve solubility of incorporated compounds. In developing its proposed products, the company intends to use modern delivery technologies, such as nanoemulsification and self-nanoemulsification; polymer-lipid mixed micelles; and solubility improvement of poorly soluble compounds for molecules with known biological activity and safety profiles.

Technology and Products

The company’s research focuses on establishing that its technology could improve solubility of poorly soluble drugs. Its technologies are in the early stage of development.

Proposed Products

Pharmaceutical Prescriptions

Intraoral (sublingual) Insulin Tablet (EGP-1214)

The proposed intraoral insulin tablet would be designed for the treatment of early stages of Type 2 diabetes, as well as for pre-diabetes. EGP-1214 is a compressed tablet containing human recombinant insulin and designed for sublingual administration for transmucosal delivery of the peptide for blood glucose management. The company is in the research phase of developing the formulation of EGP-1214.

Lorazepam Oral Spray for Emergency Treatment of Acute Seizures

The company’s proposed Lorazepam oral spray for transmucosal delivery is based on the proprietary waterless self-nanoemulsifying formula, which is designed to prevent precipitation of the active ingredient after contact with saliva. The company engages in the research phase of developing formulation of Lorazepam Oral Spray.

2% Ketoconazole Antifungal Ointment

Ketoconazole is a synthetic drug used to treat fungal infections. Structurally, Ketoconazole belongs to an Imidazole class of antifungal compounds. Topical preparations of Ketoconazole are used to treat superficial fungal infections of the skin or nails. The company is developing a topical formulation of 2% Ketoconazole ointment.

Metformin Chewable Tablets (Taste Masked)

The company’s proposed novel taste-masked composition of Metformin is intended to be chewed or administered sublingually as lozenges. The company is in the research phase of developing a chewable Metformin tablet.

Natural Health Products

E-drops Nano: E-drops Nano are nanoemulsion of essential oils combination for oral administration.

PURALEN: PURALEN is an essential oil combination for oral administration.

Glucora: Glucora is a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration. The company is developing the Glucora capsules based on self-nanoemulsifying formulation containing Banaba leaf extract and alpha-Lipoic acid.

URBAN POWER: URBAN POWER is an Ursolic acid and Banaba extract combination in soft gelatin capsule – for oral administration. The company is in the research phase of developing Urban Power with the goal of eventually formulating a marketable capsule. There is no assurance that the product would be able to reach proposed results and efficacy.

Other Proposed Products

The company’s technologies could be applied to additional products that could potentially compete with similar products already on the market. Using its existing technologies, the company is developing with a goal of commercializing three new products, such as Vitamin D3, its formulation of Vitamin D in nanoemulsion; V-Cleanzz, a vegetable wash with bactericidal components; and CleanEzze, a hand sanitizer containing essential oil.

Strategy

The key elements of the company’s strategy include developing innovative therapeutic products; and developing novel natural products and dietary supplements.

Research and Development

For the year ended December 31, 2016, the company expended $501,831 on research and development.

Manufacturing

The company has a signed agreement with Nutralab Ltd. (Markham, Ontario) to manufacture various of its products, such as E-Drops Nano, PURALEN, vitamin D3, Glucora in soft gelatin capsules and URBAN POWER soft gelatin capsules. The initial batch of 9,000 bottles of E-drops Nano was manufactured, packaged and labeled at Nutralab Ltd. in compliance with good manufacturing practice requirements.

Suppliers

The company’s suppliers for natural essential oils, suitable for oral human consumption include Citrus and Allied Essences Ltd. of Lake Success, New York. American Lecithin would be the supplier of Lecithin. Compendial high purity oils, acetylated glycerides, and pharmaceutically acceptable surfactants are being supplied by Kerry Bio-Science by way of Nealanders International, Inc., Mississauga, Ontario. Grain alcohol is supplied by Commercial Alcohols Inc., Toronto, Ontario. OptiPure (Chemco International/Kenco group), Los Angeles, California and Sabinsa Corp., East Windsor, New Jersey, are suppliers of active natural ingredients.

Intellectual Property

The company has one U.S. patent application for nanoemulsion for oral administration of essential oils (application # 2013/0029978 A1 Medicinal Compositions And Method For Treatment Of Urinary Tract Infections). Various patent applications are in preparation and would be filed in 2016 or 2017 after obtaining of supporting animal experimental data.

Competition

The company competes with Pfizer, Wyeth, Upsher-Smith Laboratories, Stiefel Laboratories, Merck, BMS, Boston Therapeutics, Biovail, and others.

Government Regulation

The company’s research and development activities and the future manufacturing and marketing of its pharmaceutical products are subject to regulation by the U.S. Food and Drug Administration (FDA) in the United States, Health Canada in Canada and comparable designated regulatory authorities in other countries. All aspects of the company’s research, development and foreseeable commercial activities relating to pharmaceutical products are subject to regulation FDA and other regulatory authorities in the United States.

History

The company was organized in 1999, under the laws of the state of Nevada. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in 2014.